Piperidine → N-(2-amino-4-{6-[3-hydroxy-3-(1,3-thiazol-2-yl)but-1-yn-1-yl]-1H-indazol-1-yl}pyrimidin-5-yl)-3-methyloxetane-3-carboxamide

Participants

Reaction Steps

To a mixture of N-[2-amino-4-(6-iodo-1H-indazol-1-yl)pyrimidin-5-yl]-3-methyloxetane-3-carboxamide (76% purity, 20 mg, 0.034 mmol) and piperidine (0.1 mL) was added tetrakis(triphenylphosphine)palladium (7.8 mg, 0.007 mmol), copper(I) iodide (1.2 mg, 0.007 mmol) and 2-(1,3-thiazol-2-yl)but-3-yn-2-ol (I-1) (10.3 mg, 0.068 mmol). The reaction was purged with N2 and stirred at RT for 2 hr. Reaction mixture was concentrated in vacuo. Purification by flash chromatography (Isolute column, 100% DCM to 2% MeOH-DCM) followed by recrystallization (1:1 MeOH-EtOAc mixture) gave the title compound: 1H NMR (500 MHz, MeOD) δ 1.73 (3H, s), 1.98 (3H, s), 4.47 (2H, d, J=5.99 Hz), 5.01 (2H, d, J=6.15 Hz), 7.43 (1H, dd, J=8.28, 1.18 Hz), 7.57 (1H, d, J=3.31 Hz), 7.79 (1H, d, J=3.31 Hz), 7.83 (1H, d, J=8.35 Hz), 8.39 (1H, s), 8.82 (1H, s), 8.92 (1H, s); m/z=+476.1 (M+H)+.

Provenance & Evidence